Sun Pharma Subsidiaries to Pay $200 Million in US Antitrust Settlement

Sun Pharmaceutical Industries Ltd has announced that its subsidiaries—Sun Pharmaceutical Industries, Inc. and Taro Pharmaceuticals U.S.A., Inc.—will jointly pay $200 million to settle claims in a major antitrust litigation in the United States.

Key Highlights

- The settlement pertains to the Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern 

District of Pennsylvania.

- The $200 million payout will be made to End Purchaser Plaintiffs in exchange for a full release of claims.

- The agreement covers current and former entities, including affiliates, directors, officers, and employees of the subsidiaries.

Legal and Strategic Context

- The settlement does not imply any admission of wrongdoing by Sun Pharma or its subsidiaries.

- The amount may be reduced if a significant number of insured class members opt out.

- The deal is subject to final approval by the overseeing US court.
Industry Implications

- The litigation is part of a broader investigation into generic drug pricing practices.

- Sun Pharma’s move reflects a strategic decision to avoid prolonged legal exposure and reputational risk.

Sources: Business Upturn, Economic Times, Reuters.